ATRANasdaqBiological Products, (No Diagnostic Substances)

Atara Biotherapeutics, Inc. (ATRA) earnings date, market-implied expected move, and options open interest by expiry

8.25

−0.23 · −2.71%

Regular session16:00 ET

Open8.26Volume17,002Mkt cap$82.3MEPS-1.11

Day8.25 – 8.550%52-wk3.92 – 19.1528%

ATRA

Atara Biotherapeutics, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Nov 11

before open · in 7 days

est.Q3 FY26

Calendar

Next report

Last report

−7.75%

shaded = implied · ▲▼ = realized

Aug 12 '26 · confirmed

Implied vs realized

Largest filed tie

—

Supply chain

13F top-10 QoQ

+94.20%

shares held · 10 largest managers

13F · Jun 30 '26127d lag

36 managers

Top fund weight

0.00%

ATRA weight · VTI

N-PORTJun 30 '26

1 fund

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Atara Biotherapeutics (ATRA) is expected to report on Nov 11 before open (estimated date).

Implied vs realized

1 report

—≥ implied

Q2 FY26Aug 12 '26confirmed—▼−7.75%—

quarterimplied−10%0+10%realized×

Q2 FY26—▼−7.75%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

No open-interest data.

Positioning

Linked exposure

No implied move.

Linked exposure

Revenue flow

as filedQ2 FY26

−767.30%as filednet margin · revenue +22.09% QoQ · −96.42% YoY

Revenue$630,000+22.09%

Gross profit$630,000100.00%+22.09%

Operating income−$5M−749.21%−40.10%

Pre-tax income−$5M−16.60%

Net income−$5M−767.30%−16.62%

Cost of revenue$0—

Operating expenses$5M+37.71%

Tax$1,000—

Other expense−$113,000+85.44%

Source: SEC filings · standardized · QE Jun 30 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 16:00 ET

Intraday

Event sensitivity

NFP ×1.40· ±7.1% vs ±5.1% · 10 releases

eventrelease day|move|up · n×base

NFPjobs report±7.1%5 of 10×1.40

CPIconsumer prices±5.9%4 of 10×1.17

PPIproducer prices±4.8%6 of 10×0.95

GDPgross domestic product±3.8%11 of 19×0.76

CPROFcorporate profits±3.5%6 of 12×0.70

PCEpersonal income & outlays±3.5%10 of 19×0.69

FOMCrate decision±3.5%13 of 24×0.68

Bar = avg |move| to ±8% · tick = ±5.1% avg day · ×base = |move| ÷ ±5.1% · min 6 releases

Earnings history

EPS -0.32 · consensus —

Quarter	Reported	EPS	Consensus
Q2 FY26	Aug 12 '26 · confirmed	-0.32	—
Q1 FY26	—	-0.29	—
Q3 FY25	—	-0.32	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod